Atherosclerosis is the main underlying cause of cardiovascular disease (CVD) and due to its multifactorial natural is often studied in animal models. Here the aim is to develop an innovative ex vivo system to study the atherosclerotic disease process based on the actual human atherosclerotic plaque. In line with the Transition to Animal-free Innovation (TPI), the aim is to develop a model that generates data on the effect of novel drugs that is highly translatable to the effect of the novel drug in the cardiovascular patient, while at the same time minimising the number of laboratory animals used. Moreover, the aim is to utilise this model to discover new biomarkers of successful treatment, which could expedite the transition of CVD therapeutic into clinical trial.
To help in the battle against COVID-19, a novel compact CT scanner will be developed to rapidly screen for disease patterns and monitor disease progression. This is done by developing a new type of compact mobile CT scanner, equipped with artificial intelligence software to detect disease patterns accurately.
The cancer grade, provided by pathologists, is the most important predictor of patient outcome, but suffers from inter- and intra-pathologist variability, reducing its usefulness for individual patients. An expert-level AI system will be provided to support pathologist and help reduce this variability and make their diagnostic practice more accurate and efficient.
The project LIF2.0 aims to develop a short term response to COVID-19 needs in industry and public organisations by offering a real time COVID-19 driven data platform covering European wide aggregated content from a vast amount of sources. Users will have insights for developing new echo period strategies.
The knowledge is missing that is essential for cost-effective roll-out of personalised treatment of insomnia. This project solves the bottleneck by creating a research platform for combined online behavioural change intervention and long-term monitoring of sleep, traits and health. A growing database will allow for optimised sleep interventions tailor to personalised needs, capacities, limitations and estimated benefits.
In muscle diseases, muscle fibers lose their capacity to contract, resulting in loss of mobility and respiration. In this project advanced 3D models of muscle diseases in vitro will be generated and the effects will be investigated on the smallest contractile unit present in muscle cells using highly sensitive force measurements.
The immune system has potent mechanisms with which it deals with intruding viruses, bacteria and tumors, protecting us from disease. However, tumors contain mutations leading to resistance to the immune system. The NextIO project aims to develop a medicine that restores the sensitivity of the cancer to the immune system.
This project aims to unravel mechanisms underlying beneficial effects of a novel food supplement on cognitive performance. This may contribute to the prevention of cognitive impairment and ultimately dementia. Focus will be on adults with an emerging pre-mild cognitive impairment condition who will benefit most from evidence-based intervention and prevention strategies.
Replacing current invasive testing by a simple blood test to enable prenatal diagnosis for pregnant couples carrying severe monogenic diseases, is much desired. In this project the aim is to develop an efficient NIPD method for monogenic diseases, for implementation in the clinic.
The aim is to improve vaccines by including viral innate immune antagonists that are co-expressed with the antigen to boost vaccine efficacy.